Sleep Disorders

blog and news, companies about African sleeping sickness, insomnia,OSA, obstructive sleep apnea, RLS, Restless Legs Syndrome, sleep maintenance, sleep architecture and sleep quality,Obstructive, Central or Complex Sleep Apnea, daytime fatigue, reduced alertness, sleep scoring, Trypanosomiasis, hypopnea syndrome, OSAHS, narcolepsy, wakefulness, sleepiness, continuous positive airway pressure (CPAP), sleep diagnostic device, Wake (time) After Sleep Onset (WASO), nasal resistance...

Tuesday, January 15, 2008

XenoPort and GlaxoSmithKline, Second Phase 3 Restless Legs Syndrome Trial for XP13512/GSK1838262

Jan 15, 2008 - XenoPort, Inc. (Nasdaq:XNPT) and GlaxoSmithKline (NYSE:GSK) announced positive top-line results from a placebo-controlled Phase 3 clinical trial designed to evaluate the potential of XP13512 (GSK1838262)

to maintain efficacy over the course of nine months in patients with moderate-to-severe primary Restless Legs Syndrome, or RLS... XenoPort's Press Release - GlaxoSmithKline 's Press Release-

Sleep Disorders

Pharmaceuticals Search Engine [selected websites]

Blog Archive

Tuesday, January 15, 2008

XenoPort and GlaxoSmithKline, Second Phase 3 Restless Legs Syndrome Trial for XP13512/GSK1838262

Link

Keywords

My Blog List

Index